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Abstract
Delirium, an acute and fluctuating disturbance of consciousness
and cognition, is a common manifestation of acute brain dys-
function in critically ill patients, occurring in up to 80% of the
sickest intensive care unit (ICU) populations. Critically ill patients
are subject to numerous risk factors for delirium. Some of these,
such as exposure to sedative and analgesic medications, may be
modified to reduce risk. Although dysfunction of other organ
systems continues to receive more clinical attention, delirium is
now recognized to be a significant contributor to morbidity and
mortality in the ICU, and it is recommended that all ICU patients be
monitored using a validated delirium assessment instrument.
Patients with delirium have longer hospital stays and lower 6-
month survival than do patients without delirium, and preliminary
research suggests that delirium may be associated with cognitive
impairment that persists months to years after discharge. Little
evidence exists regarding the prevention and treatment of delirium
in the ICU, but multicomponent interventions reduce the incidence
of delirium in non-ICU studies. Strategies for the prevention and
treatment of ICU delirium are the subjects of multiple ongoing
investigations.
Introduction
Recent advances in critical care medicine have improved
survival in patients cared for in intensive care units (ICUs)
worldwide, and in doing so they have revealed a major public
health concern that previously had been under-appreciated.
Critical care clinicians have historically been attuned to
pulmonary, cardiac, and renal dysfunction as a source of
morbidity and mortality in ICU patients but have
underestimated the impact of brain dysfunction [1]. Delirium,
a common manifestation of acute brain dysfunction in
critically ill patients, is associated with poor short-term
outcomes and may result in adverse sequelae years after ICU
discharge [2-4], and an executive summary on preventable
medical injuries commissioned by the American Association
of Retired Persons identified delirium as one of six leading
causes of injuries associated with hospitalization in patients
over 65 years of age [5]. In this article we provide a general
overview of the research to date regarding the epidemiology,
diagnosis, and pathophysiology of ICU delirium, its
association with health outcomes, and possible options for
prevention and treatment.
Definition
Delirium is defined in the American Psychiatric Association’s
(APA) Diagnostic and Statistical Manual of Mental Disorders
(DSM)-IV [6] as a disturbance of consciousness and
cognition that develops over a short period of time (hours to
days) and fluctuates over time. Many different terms have
been used to describe this syndrome of cognitive impairment
in critically ill patients, including ICU psychosis, ICU syn-
drome, acute confusional state, encephalopathy, and acute
brain failure [1,7]. However, the critical care literature has
recently conformed to the recommendations of the APA and
other experts that the term ‘delirium’ be used uniformly to
describe this syndrome of brain dysfunction.
Prevalence and subtypes
The prevalence of delirium reported in medical and surgical
ICU cohort studies has varied from 20% to 80%, depending
upon severity of illness observed and diagnostic methods
used [3,8-12]. Despite high prevalence rates in the ICU,
delirium often goes unrecognized by clinicians [13] or its
symptoms are incorrectly attributed to dementia, depression,
or ICU syndrome (considered an expected, inconsequential
complication of critical illness).
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Delirium can be categorized into subtypes according to
psychomotor behavior, and the high prevalence of hypoactive
delirium in critically ill patients probably contributes to
clinicians’ lack of recognition of delirium. Hypoactive delirium
is characterized by decreased responsiveness, withdrawal,
and apathy, whereas hyperactive delirium is characterized by
agitation, restlessness, and emotional lability [14]. Peterson
and coworkers [15] examined delirium subtypes in a cohort of
ventilated and nonventilated medical ICU patients, and they
observed that purely hyperactive delirium was rare (1.6%). In
contrast, 43.5% of patients had purely hypoactive delirium
and 54.1% had mixed delirium. Among non-ICU patients,
hyperactive delirium has been associated with a better
prognosis than hypoactive delirium [16], but this relationship
has not been evaluated thoroughly among ICU patients.
Because it is clear, however, that delirium is associated with
poor clinical outcomes in critically ill patients, routine
monitoring using valid and reliable delirium diagnosis instru-
ments is recommended in all ICUs so that the prognostic
significance of delirium does not go unnoticed.
Another important categorization scheme was recently
studied in the critical care literature. Ouimet and colleagues
[17] evaluated 600 ICU patients for symptoms of delirium
and categorized them according to the number of symptoms
present. Patients with no symptoms were considered to have
‘no delirium’, those with four or more symptoms to have
‘clinical delirium’, and those with one to three symptoms to
have ‘subsyndromal delirium’ (because the full syndrome,
according to DSM-IV criteria, was not present). This important
study corroborated in the ICU setting a finding that had
previously been reported from non-ICU studies; subsyndromal
delirium represents an intermediate state that is different from
both clinical delirium and a normal neurologic state.
Prognostic significance
Among medical ICU patients, delirium is associated with
multiple complications and adverse outcomes, including self-
extubation and removal of catheters [9], failed extubation
[18], prolonged hospital stay [2], increased health care costs
[19], and increased mortality [3,20,21]. Ely and coworkers
[3] studied 275 mechanically ventilated medical ICU patients
and determined that delirium was associated with a threefold
increase in risk for 6-month mortality after adjusting for age,
severity of illness, co-morbidities, coma, and exposure to
psychoactive medications. The association between ICU
delirium and increased mortality was subsequently confirmed
in two other cohort studies [20,21].
Delirium may be a predictor of long-term cognitive impairment
in survivors of critical illness. Jackson and colleagues [4]
reviewed nine prospective studies that included nearly 1,900
non-ICU patients who were hospitalized for medical and
surgical treatments, and reported that delirium was associa-
ted with cognitive decline over 1 to 3 years after hospital
discharge. The relationship between ICU delirium and long-
term cognitive impairment is the subject of ongoing investi-
gations, but preliminary data suggest that the association is
significant. Jackson and coworkers [22] recently examined
this association in 98 patients who were mechanically
ventilated for acute respiratory failure in medical ICUs.
Prolonged periods of ICU delirium were associated with an
increased risk for long-term cognitive impairment at 3 months
post-discharge after adjusting for covariates (P < 0.001).
Pathophysiology
The pathophysiology of delirium is poorly understood but
multiple promising hypotheses are subjects of ongoing
research. The majority of studies supporting the hypotheses
reviewed here were conducted in non-ICU patients. Thus,
significant research is needed to elucidate the complex
interplay between the mechanisms of critical illness and ICU
delirium.
Neurotransmitter imbalance
Delirium is theorized to be a neurobehavioral manifestation of
imbalances in the synthesis, release, and inactivation of
neurotransmitters that normally control cognitive function,
behavior, and mood [23]. Derangements of multiple neuro-
transmitter systems have been implicated in the patho-
physiology of delirium, with the greatest focus being given to
dopamine and acetylcholine. These neurotransmitters work in
opposition, with dopamine increasing and acetylcholine
decreasing neuronal excitability. An imbalance in one or both
of these neurotransmitters results in neuronal instability and
unpredictable neurotransmission. Specifically, an excess of
dopamine [24] or depletion of acetylcholine [25] have been
associated with delirium. Other neurotransmitters are likely to
play a role in the pathogenesis of delirium as well, including γ-
aminobutyric acid (GABA), serotonin, endorphins, and
glutamate [23].
Inflammation
Inflammation plays a significant role in the dysfunction of
multiple organs caused by critical illness [26], and inflam-
matory abnormalities induced by endotoxin and cytokines
probably contribute to the development of ICU delirium.
Inflammatory mediators produced during critical illness (for
example, tumor necrosis factor-α, interleukin-1, and other
cytokines and chemokines) initiate a cascade of endothelial
damage, thrombin formation, and microvascular compromise
[27]. Studies in animal models have revealed that these
inflammatory mediators cross the blood-brain barrier [28],
increase vascular permeability in the brain [29], and result in
changes on electroencephalography (EEG) that are consis-
tent with those seen in septic patients with delirium [30].
Inflammation may incite brain dysfunction by decreasing
cerebral blood flow via the formation of microaggregates of
fibrin, platelets, neutrophils, and erythrocytes in the cerebral
microvasculature; by constricting cerebral vasculature
through activation of α1-adrenoceptors [31]; or by interfering
with neurotransmitter synthesis and neurotransmission [32].Page 3 of 9
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Impaired oxidative metabolism
Early hypotheses that remain relevant today attempted to
explain delirium as a behavioral manifestation of a ‘wide-
spread reduction of cerebral oxidative metabolism resulting in
an imbalance of neurotransmission’ [33]. Engel and Romano
[34] conducted classic experiments by evaluating delirious
patients using EEG. These studies showed that delirium is
associated with diffuse slowing on EEG, a finding that is
believed to represent a reduction in brain metabolism. Thus,
they hypothesized that delirium is the result of ‘cerebral
insufficiency’ (a global failure of cerebral oxidative meta-
bolism), a factor that is known to be important in the patho-
genesis of multiple organ dysfunction in critical illness [35].
Availability of large neutral amino acids
Neurotransmitter levels and function can be affected by
changes in the plasma concentrations of various amino acid
precursors, and some investigators have proposed that
altered availability of large neutral amino acids contributes to
the development of delirium [32]. Amino acid entry into the
brain is regulated by a sodium-independent large neutral
amino acid transporter type 1 (LAT1) [36]. Tryptophan, an
essential amino acid and precursor for serotonin, competes
with several large neutral amino acids (for example, tyrosine,
phenylalanine, valine, leucine, and isoleucine) for transport
across the blood-brain barrier via LAT1 transporters.
Phenylalanine also competes with large neutral amino acids
for transport across the blood-brain barrier. Increased
cerebral uptake of tryptophan and phenylalanine, compared
with that of other large neutral amino acids, leads to elevated
levels of dopamine and norepinephrine (noradrenaline), two
neurotransmitters that have been implicated in the
pathogenesis of delirium [33].
Risk factors
Risk factors for delirium can be divided into predisposing
factors (host factors) and precipitating factors [37]. Although
predisposing factors are present before ICU admission and
are difficult to alter, precipitating factors occur during the
course of critical illness. They may involve factors of the acute
illness or be iatrogenic; these factors represent areas of risk
that are potentially modifiable by preventive or therapeutic
intervention.
Only a few studies have examined risk factors for delirium in
the ICU, but numerous delirium risk factors have been
identified in non-ICU patients. Table 1 highlights factors that
have been identified in both ICU and non-ICU studies. In the
largest study to date that examined risk factors for ICU
delirium, Ouimet and coworkers [21] studied 820 general
ICU patients and determined that hypertension, alcoholism,
severity of illness, and exposure to sedatives and analgesics
(when used to induce coma) increased the likelihood of
delirium. Dubois and colleagues [9] similarly found hyper-
tension to be a risk factor for delirium among 216 general
ICU patients. In addition, smoking history, hyperbilirubinemia,
morphine, and analgesia administered via an epidural route
were associated with delirium. To date, however, no study
has corroborated this association between analgesia
administered via an epidural route and delirium.
In the only study to date to examine whether there is a
genetic predisposition to ICU delirium in some patients, Ely
and coworkers [38] evaluated the association between
apolipoprotein E (APOE) genotype and duration of delirium
among 53 mechanically ventilated medical ICU patients.
Patients with the APOE4 polymorphism (a risk factor for
Alzheimer’s disease) were delirious for twice as long as those
without the APOE4 polymorphism (median [interquartile
range]: 4 [3 to 4.5] days versus 2 [1 to 4] days; P = 0.05).
Larger studies are ongoing to confirm this association.
Other factors associated with delirium in the ICU include
older age, baseline cognitive impairment, metabolic distur-
bances (for instance, derangements in sodium, calcium, and
blood urea nitrogen), acute infection, respiratory disease,
acidosis, anemia, and hypotension [10,39,40]. Some factors
that are clearly associated with delirium in hospitalized
patients without critical illness may carry similar risks among
ICU patients, although studies to date have not yet proven
associations with ICU delirium. These potential risk factors
include hearing or vision impairment, depression, and
immobilization resulting from placement of catheters or
restraints [37,41]. Critically ill patients are typically exposed
to numerous factors that may precipitate delirium. In a study
of 53 medical ICU patients, Ely and coworkers [2] identified
an astounding average of 11 delirium risk factors per patient.
Two delirium risk factors nearly universally experienced by
ICU patients are exposure to sedative and analgesic
medications and sleep deprivation. The risk associated with
both of these factors is potentially modifiable, as is discussed
in greater detail below.
Sedative and analgesic medications
Sedative and analgesic medications are routinely adminis-
tered to patients receiving mechanical ventilation to reduce
pain and anxiety, as recommended by the Society of Critical
Care Medicine (SCCM) [42]. These medications, however,
are not without detrimental effects. Continuous intravenous
sedation, for example, is associated with prolonged
mechanical ventilation as compared with sedation via inter-
mittent boluses [43].
Multiple studies have demonstrated an association between
delirium and exposure to sedative and analgesic medications.
In a mixed surgical/medical ICU, Dubois and coworkers [9]
determined that morphine was the strongest predictor of
delirium in a multivariable model. Ouimet and colleagues [21]
observed that sedative and analgesic medications used to
induce coma were associated with delirium (delirium among
patients with drug-induced coma: odds ratio [OR] = 3.2,
95% confidence interval [CI] = 1.5 to 6.8). Marcantonio and
Available online http://ccforum.com/content/12/S3/S3coworkers [44] reported that patients treated with benzo-
diazepines were more likely to have postoperative delirium
than were those not treated with benzodiazepines (OR = 2.7,
95% CI = 1.3 to 5.5). Meperidine also increased the likelihood
of postoperative delirium (OR = 3.0, 95% CI = 1.3 to 6.8).
A recent study examined the temporal relationship between
administration of sedatives and analgesics and ICU delirium.
Pandharipande and colleagues [40] used Markov regression
modeling to determine that lorazepam is an independent risk
factor for daily transition to delirium (OR = 1.2, 95% CI = 1.2
to 1.4); specifically, patients treated with lorazepam on a
given ICU day are more likely to be delirious on the following
day than if lorazepam were not administered (Figure 1).
Treatment with fentanyl, morphine, and propofol were not
significantly associated with transition to delirium, but larger
studies are ongoing to examine further the associations of
these medications with delirium. Midazolam was shown to
increase the likelihood of transition to delirium in another
recently completed study of trauma and surgical ICU
patients [11].
Sedative agents that are GABA receptor sparing, such as
opioids and dexmedetomidine (a novel α2-receptor agonist),
may reduce the risk for delirium in ICU patients as compared
with the risk attributable to benzodiazepines. Although
studies have consistently identified lorazepam and
midazolam as risk factors for delirium, the data regarding
opioids are less consistent. For example, Ouimet and
coworkers [21] noted that mean daily opioid doses were
higher among ICU patients without delirium than among ICU
patients with delirium. Similarly, in 541 hip fracture patients,
Morrison and colleagues [45] determined that those treated
liberally with opioid analgesics (>10 mg/day parenteral
morphine sulfate equivalent) were less likely to develop
delirium than patients who received less analgesia.
Treatment with meperidine was an exception, because this
drug increased the risk for delirium as compared with other
opioids. These investigations point to the importance of
judicious use of these psychoactive medications, with focus
on adequate analgesia.
Sleep disturbances
Although the association between sleep disturbances and
ICU delirium has not been studied, sleep deprivation impairs
cognition [46] and the relationship between sleep during
critical illness and delirium is a promising area of ongoing
research. On average, ICU patients sleep only 2 hours per
day [47], and less than 6% of their sleep is random eye
movement sleep. Cooper and coworkers [48] studied 20
mechanically ventilated ICU patients using polysomnography
and observed that every patient had severely disrupted sleep
or none at all. Such disturbances may detrimentally affect
protein synthesis, cellular and humoral immunity, and energy
expenditure, and ultimately they may contribute to organ
dysfunction such as delirium. Excessive noise and patient
care activities account for only a minority of arousals in ICU
patients, whereas metabolic derangements, mechanical
ventilation, and exposure to sedative and analgesic medica-
tions probably play significant roles in disturbing sleep in the
ICU [49]. Because sedative and analgesic medications may
lead directly to delirium or may contribute to impaired
Critical Care    Vol 12 Suppl 3 Girard et al.
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Table 1
Risk factors for delirium in ICU patients
Host factors Factors of critical illness Iatrogenic factors
Age (older) Acidosis Immobilization (for example, catheters, restraints)
Alcoholism Anemia Medications (for example, opioids, benzodiazepines)
APOE4 polymorphism Fever/infection/sepsis Sleep disturbances
Cognitive impairment Hypotension
Depression Metabolic disturbances (for example, 
Hypertension sodium, calcium, BUN, bilirubin)
Smoking Respiratory disease
Vision/hearing impairment High severity of illness
The table includes factors associated with delirium in both intensive care unit (ICU) and non-ICU studies. APOE4, apolipoprotein E4; BUN, blood
urea nitrogen.
Figure 1
Lorazepam and the probability of transitioning to delirium. The
probability of transitioning to delirium increased with the dose of
lorazepam administered during the previous 24 hours. This incremental
risk was large at low doses and plateaued at approximately 20 mg/day.
Data from Pandharipande and coworkers [40].cognition via disruption of sleep, and because traditional
methods of sedation and analgesia are amenable to change,
some investigators have prioritized studies seeking to
understand the relationships between sedative and analgesic
exposure, sleep disturbance, and brain dysfunction in
critically ill patients.
Diagnosis of delirium in the intensive care
unit
Delirium assessment instruments, such as the Intensive Care
Delirium Screening Checklist (ICDSC) [8] and the Confusion
Assessment Method for the ICU (CAM-ICU) [50,51] allow
nonpsychiatric physicians and other ICU personnel to
diagnose delirium in ICU patients rapidly and reliably, even
when the patient cannot speak because of endotracheal
intubation. In fact, the SCCM [42] recommends that all ICU
patients be routinely evaluated for delirium.
Bergeron and colleagues [8] validated the ICDSC in a study
of 93 ICU patients who were evaluated by a consulting
psychiatrist who served as the reference standard rater.
Using the ICDSC, each patient is assigned a score from 0 to
8; a cut-off score of 4 has a sensitivity of 99% and specificity
of 64% for identifying delirium. Thus, because of its very high
sensitivity, the authors recommend that the ICDSC be used
as a screening tool for ICU delirium.
When using the ICDSC, level of consciousness is first rated
on a 5-point scale that ranges from unresponsive to exagger-
ated response (Table 2). Any patient who is not comatose or
stuporous (A or B on the ICDSC scale) is then assessed for
items on the checklist using information collected during the
previous 24 hours. Including altered level of consciousness,
the ICDSC consists of eight items (rated present or absent),
and each patient is given a score from 0 to 8 (Table 2); 4 or
greater is considered diagnostic of delirium.
The CAM-ICU, adapted from the Confusion Assessment
Method [52], was designed for use in intubated patients and
validated against a reference standard rater in mechanically
ventilated ICU patients. Originally validated by Ely and
coworkers [50,53] in two cohorts of 38 and 111 medical ICU
patients, the CAM-ICU has a high sensitivity (93% to 100%)
and specificity (89% to 100%) for delirium as well as high
inter-rater reliability (κ = 0.96, 95% CI = 0.92 to 0.99). Lin
and colleagues [20] subsequently validated the CAM-ICU in
a separate cohort of 102 mechanically ventilated medical ICU
patients and reported similarly high sensitivity (91% to 95%),
specificity (98%), and inter-rater reliability (κ = 0.91).
Using the CAM-ICU, delirium is diagnosed in two steps
(Figure 2). Level of consciousness (level of arousal) is first
assessed using a standardized sedation scale. One example,
the Richmond Agitation-Sedation Scale (RASS) [54,55], is a
10-point scale ranging from +4 to -5, with a RASS score of 0
denoting a calm and alert patient. By convention, RASS
scores of -4 and -5 identify coma; a comatose patient cannot
be assessed for delirium. All other patients, whether
moderately sedated (RASS score -3) or more alert, should be
evaluated for delirium. The CAM-ICU assesses patients for
four features of delirium; three out of four features are
required for a diagnosis of delirium (Figure 2).
Prevention and treatment
Multicomponent strategies
Interventions aimed at preventing delirium have not been
adequately studied in critically ill patients (Table 3), and a
higher rate of incident delirium (delirium present upon
admission to the ICU or upon recovery from coma) in critically
ill patients compared with that observed in hospitalized
patients without critical illness may indicate that preventive
strategies that are effective in non-ICU patients may be less
likely to prevent delirium in the ICU. However, a review of
studies of delirium prevention in non-ICU patients may inform
ICU practitioners regarding appropriate management of high-
risk patients treated in the ICU.
In a landmark trial, Inouye and coworkers [56] evaluated 852
hospitalized older patients who were nonrandomly assigned
to usual care or management with a multicomponent
Available online http://ccforum.com/content/12/S3/S3
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Table 2
The Intensive Care Delirium Screening Checklist
Checklist Item Description
Altered level of consciousnessa
A No response
B Response to intense and repeated 
stimulation
C Response to mild or moderate stimulation
D Normal wakefulness
E Exaggerated response to normal 
stimulation
Inattentiveness Difficulty following instructions or easily 
distracted
Disorientation To time, place, or person
Hallucination-delusion- Clinical manifestation or suggestive 
psychosis behavior
Psychomotor agitation  Agitation requiring use of drugs or 
or retardation restraints, or slowing
Inappropriate speech or  Related to events or situation, or 
mood incoherent speech
Sleep/wake cycle  Sleeping <4 hours/day, waking at night, 
disturbance sleeping all day
Symptom fluctuation Symptoms above occurring intermittently
Total score 0 to 8
aIf A or B, then no other items are assessed that day. Data are from
Bergeron and coworkers [8].intervention consisting of multiple protocols designed to
minimize the effects of delirium risk factors. These protocols
directed repeated reorientation of the patient and provision of
cognitively stimulating activities; a nonpharmacologic sleep
protocol; early mobilization activities and range of motion
exercises; timely removal of catheters and physical restraints;
use of eyeglasses, magnifying lenses, and hearing aids; and
early correction of dehydration. The intervention significantly
reduced the incidence of delirium (15.0% in the usual care
group versus 9.9% in the intervention group; matched OR =
0.60, 95% CI = 0.39 to 0.92). These results were confirmed
in randomized trials studying the efficacy of multicomponent
delirium prevention programs in postoperative patients [57]
and geriatric inpatients [58].
Although the strategies emphasized in these studies (for
instance, frequent reorientation, restoration of sleep/wake
cycles, timely removal of catheters, early mobilization, and
minimization of unnecessary noise/stimuli) are recommended
for ICU patients, such strategies have not been studied in the
ICU, and the nature and number of delirium risk factors in ICU
patients are different from those observed among other
inpatients. Preventive interventions, therefore, must address
those risk factors that are most common in the ICU, including
electrolyte abnormalities, infection, and exposure to sedative
and analgesic medications. These drugs play a vital role in
maintaining patient comfort, and adequate pain control is
likely to reduce the risk for delirium [45], but practitioners
must strive to avoid over-sedation by administering the drugs
only as necessary. In fact, sedation protocols that use
validated sedation scales [59], emphasizing intermittent
boluses rather than continuous infusions [43], and promoting
daily interruption of sedatives and analgesics [60] signifi-
cantly improve multiple clinical outcomes. The effect of these
methods of sedation on delirium is the subject of ongoing
investigations.
Pharmacologic strategies
After the ICU team has used the multicomponent prevention
strategies described above to minimize risk factors and after
acute, life-threatening complications of critical illness that
may lead to delirium (for example, hypoxia, hypercapnia, hypo-
glycemia, and shock) have been sought out and addressed,
pharmacologic therapy for the prevention and treatment of
delirium should be considered (Table 3). When using such
medications, clinicians should be aware that any drug
intended to improve cognition may have adverse psycho-
active effects, paradoxically exacerbating delirium or causing
excessive sedation in some patients. Also, evidence proving
the efficacy of pharmacologic strategies for delirium is
lacking. All psychoactive drugs should therefore be used
judiciously in critically ill patients, in the smallest effective
dose for the shortest time necessary.
Although no placebo-controlled clinical trials have been
conducted to evaluate its efficacy in ICU patients, haloperidol
is recommended as the drug of choice for the treatment of
ICU delirium by the SCCM [42] and the APA [61]. A typical
antipsychotic, haloperidol blocks D2 dopamine receptors,
resulting in amelioration of hallucinations, delusions, and
unstructured thought patterns. The optimal dose and regimen
have not been defined in clinical trials, but the SCCM
guidelines suggest that patients with hyperactive delirium
should be treated with 2 mg intravenously, followed by
repeated doses (doubling the previous dose) every 15 to
20 minutes while agitation persists. Once the agitation subsides,
scheduled doses (every 4 to 6 hours) may be continued for a
few days, followed by tapered doses for several days.
Common doses for ICU patients range from 4 to 20 mg/day,
but higher doses are frequently used for the treatment of
acute agitation. Also, haloperidol has been evaluated as a
Critical Care    Vol 12 Suppl 3 Girard et al.
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Figure 2
The Confusion Assessment Method for the Intensive Care Unit. 
*Level of consciousness (depth of sedation) is assessed using the
Richmond Agitation-Sedation Scale (RASS) [54,55]. 
†Content of consciousness is assessed (delirium is diagnosed) using
the Confusion Assessment Method for the ICU (CAM-ICU) [50,53].
When three of four diagnostic features are present (either features 1,
2, and 3, or features 1, 2, and 4), delirium is diagnosed. Data from Ely
and coworkers [50] and the CAM-ICU training manual [51].prophylactic therapy for the prevention of postoperative
delirium in elderly hip surgery patients. Kalisvaart and
coworkers [62] conducted a randomized, double-blind,
placebo-controlled trial in 430 elderly hip surgery patients
and determined that 1.5 mg/day haloperidol significantly
reduced the severity and duration of delirium. The incidence
of delirium was not altered by haloperidol compared with
placebo. A similar trial is currently ongoing in ICU patients.
Atypical antipsychotics (for instance, risperidone, ziprasidone,
quetiapine, and olanzapine) may also be helpful in the
treatment of delirium, but only preliminary data exist
supporting their use in the ICU. These medications target
dopamine receptors as well as receptors for other neuro-
transmitters, including serotonin, acetylcholine, and nor-
epinephrine (noradrenaline). Skrobik and coworkers [63]
compared olanzapine with haloperidol in a nonrandomized
trial that enrolled 73 medical and surgical ICU patients; they
reported that resolution of delirium symptoms was similar in
both treatment groups, but more side effects were observed
in patients treated with haloperidol. Numerous studies have
compared different antipsychotics with each other for the
treatment of delirium in non-ICU patients, but all are limited by
the absence of a placebo-treated control group as well as by
other methodologic limitations [64]. Well designed, rando-
mized, placebo-controlled trials are needed to inform critical
care clinicians regarding the efficacy and safety of both
typical and atypical antipsychotics in the prevention and
treatment of ICU delirium.
Patients treated with haloperidol or other antipsychotics
should be monitored for adverse effects, including hypo-
tension, dystonia, extrapyramidal effects, laryngeal spasm,
malignant hyperthermia, glucose and lipid dysregulation, and
anticholinergic effects such as dry mouth, constipation, and
urinary retention. Torsades de pointes is a life-threatening
arrhythmia that may occur in patients treated with
antipsychotics, and these medications should be avoided in
patients with prolonged QT intervals.
Recently, investigators observed an association between anti-
psychotic use (typical or atypical) and increased mortality in
elderly patients [65,66]. The patients studied were not
critically ill, and no study of ICU patients has demonstrated an
increased risk for death due to antipsychotic use. In fact,
Milbrandt and coworkers [67] studied 989 mechanically
ventilated ICU patients and observed that haloperidol was
associated with significantly lower hospital mortality.
Although they remain the drugs of choice for the treatment of
delirium tremens (and other withdrawal syndromes), benzo-
diazepines are not recommended for the management of
delirium because these medications are themselves risk
factors for delirium [21,40,44]. Dexmedetomidine, a novel α2-
receptor agonist that does not act on GABA receptors, may
prove to be an alternative sedative agent that is less likely to
cause delirium. In a preliminary report of an unblinded,
randomized trial conducted in postoperative cardiac surgical
patients, Maldonado and colleagues [68] described a
significant reduction in the incidence of delirium associated
with dexmedetomidine; 8% of patients sedated with dex-
medetomidine at sternal closure developed delirium as
compared with 50% of patients sedated with propofol or
midazolam. Similarly, in a recently completed double-blind,
randomized controlled trial [69] it was determined that ICU
patients sedated with dexmedetomidine spent fewer days in
coma and more days neurologically normal (without coma or
delirium) than did those sedated with lorazepam. These pilot
studies suggest that larger trials are warranted to evaluate
the efficacy and safety of sedation with dexmedetomidine as
well as clonidine, a less selective α2-receptor agonist, in ICU
patients.
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Table 3
Interventions for the prevention and treatment of ICU delirium
Intervention Effecta Supporting evidenceb
Nonpharmacologic
Multicomponent strategy Prevention Non-ICU clinical trials [56,58]
Geriatrics consultation Prevention Non-ICU clinical trials [57]
Reduced benzodiazepine use Prevention Prospective ICU cohort studies [40]
Pharmacologic
Haloperidol Both Placebo-controlled, randomized, non-ICU trial [62]
Olanzapine Treatment Non-randomized ICU trial [63]
Adequate analgesia Prevention Prospective non-ICU cohort studies [45]
Dexmedetomidine Prevention Randomized ICU trials [68,69] 
aAlthough each intervention may have a role in both the prevention and treatment of intensive care unit (ICU) delirium, most have only been studied
in one role or the other. bReferences highlight prototypical studies and do not represent an exhaustive review of the literature.Conclusion
Delirium is a common manifestation of acute brain dys-
function in critically ill patients that is associated with poor
short-term outcomes and may result in adverse sequelae
years after ICU discharge. The strategies described here for
the prevention, diagnosis, and treatment of ICU delirium are
subjects of multiple ongoing investigations. Every ICU
clinician should be aware of these strategies, institute routine
monitoring for delirium in the ICU, seek to reduce the impact
of risk factors for delirium when possible, and use treatment
options when necessary.
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